---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-037619"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:27:00.849025+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Gilead completes $4.3B acquisition of CymaBay; seladelpar added to liver pipeline

## Summary
- Total equity value ~$4.3 billion; Gilead paid $32.50 per CymaBay share.
- Tender offer resulted in 77.3% of shares tendered (93.7M shares); remaining shares converted at same price.
- CymaBay becomes wholly owned subsidiary; CBAY to be delisted from Nasdaq on March 22, 2024.
- Transaction expected to reduce Gilead's 2024 GAAP/non-GAAP EPS by $3.10-$3.20; including costs, $3.35-$3.45 relative to prior guidance.
- Seladelpar (for primary biliary cholangitis) is key asset; safety/efficacy not yet established.

## SEC filing metadata
- accession: 0001104659-24-037619
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000110465924037619/0001104659-24-037619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000110465924037619/tm249475d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-037619
- JSON: https://secwatch.observer/filing/0001104659-24-037619.json
- Plain text: https://secwatch.observer/filing/0001104659-24-037619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.